| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.00▼ | 1.00▼ | 0.99▲ | 1.00▼ | 1.10▼ |
| MA10 | 1.00▼ | 0.99▲ | 0.99▲ | 1.03▼ | 1.31▼ |
| MA20 | 0.99▲ | 0.99▲ | 1.01▼ | 1.09▼ | 1.78▼ |
| MA50 | 1.04▼ | 1.03▼ | 1.05▼ | 1.36▼ | N/A |
| MA100 | 1.08▼ | 1.11▼ | 1.11▼ | N/A | N/A |
| MA200 | 1.15▼ | 1.20▼ | 1.30▼ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | 0.004▲ | 0.003▲ | 0.008▲ | N/A |
| RSI | 45.240▼ | 44.033▼ | 42.520▼ | 33.043▼ | 18.255▼ |
| STOCH | 62.760 | 57.877 | 64.559 | 13.764▼ | 8.479▼ |
| WILL %R | -57.255 | -32.444 | -32.444 | -93.463▼ | -97.744▼ |
| CCI | 41.050 | 85.480 | 79.336 | -89.236 | -123.484▼ |
| ▲ GAP | $VRXA Open Gap Up %2 | Set Alert |
|
Wednesday, October 21, 2026 05:10 AM
VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while ...
|
|
Thursday, October 15, 2026 10:39 AM
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo ...
|
|
Monday, October 12, 2026 07:06 PM
(MENAFN- Investor Brand Network) VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/10/26 | 1.02 | 1.02 | 0.97 | 0.98 | 68,905 |
| 27/10/26 | 1.00 | 1.02 | 0.98 | 0.9997 | 95,381 |
| 26/10/26 | 1.00 | 1.03 | 0.95 | 0.98 | 162,839 |
| 23/10/26 | 1.04 | 1.06 | 0.9895 | 1.00 | 137,870 |
| 22/10/26 | 1.08 | 1.08 | 1.03 | 1.03 | 170,603 |
| 21/10/26 | 1.05 | 1.13 | 1.05 | 1.06 | 197,870 |
| 20/10/26 | 1.09 | 1.09 | 0.99 | 1.01 | 126,090 |
| 19/10/26 | 1.10 | 1.10 | 1.00 | 1.00 | 118,366 |
| 16/10/26 | 1.15 | 1.15 | 1.08 | 1.11 | 127,281 |
| 15/10/26 | 1.13 | 1.15 | 1.06 | 1.10 | 114,458 |
|
|
||||
|
|
||||
|
|